Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.41 |
| ▸ | KDR | P35968 | 7/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974090 | 0.87 | HPGD (0.38) | HPGDKDRSMN1; SMN2FGFR1SRC | |
| SCHEMBL2976802 | 0.87 | GABRP (0.39) | HPGDKDRSMN1; SMN2FGFR1 | |
| SCHEMBL2966412 | 0.84 | HPGD (0.42) | HPGDKDRALDH1A1NPC1GLA | |
| SCHEMBL2652694 | 0.77 | HPGD (0.37) | HPGDKDRSMN1; SMN2FGFR1 | |
| SCHEMBL2652208 | 0.77 | SIGMAR1 (0.43) | HPGDKDRDRD4SIGMAR1ALDH1A1 | |
| SCHEMBL2964598 | 0.77 | FGFR1 (0.48) | HPGDALDH1A1NPC1GLARAB9A | |
| SCHEMBL2652210 | 0.73 | HPGD (0.42) | HPGDKDRDRD4SIGMAR1ALDH1A1 | |
| SCHEMBL2976787 | 0.72 | HPGD (0.38) | HPGDKDRSMN1; SMN2FGFR1SRC | |
| SCHEMBL2967387 | 0.72 | GABRP (0.37) | HPGDKDRALDH1A1SMN1; SMN2FGFR1 | |
| SCHEMBL2651808 | 0.70 | FGFR1 (0.40) | HPGDKDRFGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | claimed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | claimed |
| US-7776900-B2 | Benzimidazole derivatives and their use for modulating the GABAAreceptor complex | NEUROSEARCH A/S (DK) | 2010-08-17 | — | — | US | disclosed |
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | ANIONA APS (DK) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030018-A1 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex | GABRB2, GABRB1, GABRB3 | HPGD 1855/4885KDR 4113/4885DRD4 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.